Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Safety and PK Study of BRII-196 in Healthy Volunteers
NCT04479631Phase 1Completed
- Sponsor
- Brii Biosciences
- Start
- Jul 2020
- Primary completion
- Jan 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of amubarvimab in coronavirus disease 2019 (COVID-19) (3 cohorts), sponsored by Brii Biosciences. Primary endpoints: Incidence of adverse events (AEs) by CTCAE v5.0 up to 24 weeks, Proportion of subjects with SAEs up to 24 weeks and 2 more. Started Jul 2020; status: completed.
02
Drugs
amubarvimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04479631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04479631.